Yellow Fever
39
2
5
25
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
2.6%
1 terminated out of 39 trials
96.2%
+9.6% vs benchmark
33%
13 trials in Phase 3/4
36%
9 of 25 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 25 completed trials
Clinical Trials (39)
A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults
A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers
Phase 3 Single Arm, Open Study on vYF in Adults
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination
Human Immune Responses to Yellow Fever Vaccination
Trial of an Inactivated Yellow Fever Virus Vaccine
Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination
Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA
Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia
A Pilot Study to Finetune Skin Processing Procedures in Recent Vaccinees, Prior to GeKoSkimm Study Initiation (GeKoSkimm-pilot)
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL
Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine
Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old
Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months
Immunogenicity of Yellow Fever Vaccine in a Pediatric Population Vaccinated at 12-23 Months of Age in Argentina
Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination
Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection
Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants